Metro family embraces life with baby battling rare, fatal genetic disorder
OLATHE, Kan. — Five months ago, Christina and Adam Hannan were celebrating the arrival of their sixth child, a beautiful baby girl named Annalise.
But the joy of her birth quickly turned to heartbreak. Annalise wasn't crying. She wasn't moving. Something was wrong.
KC-area emergency management on staying prepared ahead of severe weather
Doctors diagnosed her with congenital hypomyelinating neuropathy, a condition so rare that fewer than 50 cases have ever been recorded worldwide, and only seven people are known to be living with it today.
It affects the development of nerves, leaving babies with very low muscle tone. They can't swallow, cry, or even cough. Most don't live past the age of three.
'This is Annalise,' her father Adam says. 'Annalise was born with a super rare genetic disorder.'
What makes Annalise's story even more unbelievable—the Hannans have lived this nightmare before.
Fourteen years ago, their son Myles was born with the same rare disorder.
'We know one of the 50 because he was our son,' Adam said. 'We had a son with this same condition' Adam continued on to say.
Myles lived for just 20 months.
So, this time around, every moment with Annalise matters even more.
Annalise doesn't cry. She breathes through a trach. She eats through a feeding tube. And each night, she sleeps connected to a ventilator.
Yet to her parents, she is not defined by tubes or machines. She's defined by joy.
'It's horrible, but every day is a gift. So you wake up, and it's like—we have today' Christina Hannan, Annalise's mother said.
'It's both hard and good at the same time, our mission is to let her know that she is loved—as much and as often as we can,' Adam said.
That mission is shared with Annalise's four siblings, who help care for their baby sister with quiet strength and compassion.
The Hannans are not sugarcoating the pain. They live in the tension of knowing their daughter could pass away at any moment. But they refuse to live in fear.
View the latest Weather Alerts in the Kansas City region on FOX4
'We have to – that the thing you have to put one foot in front of the other you just have to there's no choice so we proceed with joy,' Adam said.
Annalise may never walk or speak. But she feels love, she shows joy and she matters.For the Hannans, that's everything.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Everything you need to know about headaches for Headache Awareness Month
NEW HAVEN, Conn. (WTNH) — June is Headache Awareness Month. In today's health headlines, we discuss what to know about the most common headache types, how to tell them apart, and tips for preventing a tension headache. Dr. Vanessa Cooper, Yale Medicine neurologist specializing in headaches and assistant professor at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss. Watch the video above to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 membrane transporter and reduced vascular calcification in animal models of CKD BOSTON, June 06, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., ('Rectify') a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today showcased new data from its cardiorenal program with its ABCC6-targeting PFM, RTY-822. The results were presented in an oral presentation during the European Renal Association (ERA) 2025 Congress, taking place in Vienna, Austria, June 4 – 7, 2025. 'These translational results demonstrate that Rectify's PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,' said Rajesh Devraj, Ph.D., President and Chief Executive Officer of Rectify. 'We believe the strength of these data underscores the potential of our approach to offer a novel and differentiated therapeutic strategy to treat renal dysfunction and injury, as well as address vascular calcification driving cardiovascular disease. We are committed to continuing to advance meaningful therapies for patients with CKD and serious cardiovascular conditions.' Robert Hughes, Ph.D., Chief Scientific Officer of Rectify, added, 'Enhancing the function of ABCC6 holds the potential to address key drivers of vascular calcification and tubular dysfunction seen in CKD. With demonstrated on-target engagement, RTY-822 shows significant promise to reduce CKD-associated calcium deposits in arterial walls, a well-established contributor to cardiovascular morbidity and mortality seen in patients with CKD, and remarkably, also improves glomerular function and tubular injury. The translational readiness of this program makes it a compelling de-risked asset with the potential to address CKD and multiple cardiovascular indications.' Title: A Positive Functional Modulator of ABCC6 Decreases Vascular Calcification and Improves Kidney Function in a Rat Adenine Diet Model of Chronic Kidney DiseaseAbstract Number: 1723 Presenter: John Miller, Ph.D. Session: Chronic Kidney Disease, Focused Oral Room 4Date and Time: Friday, June 6, 2025, 8:51 a.m. – 8:57 a.m. CEST In CKD, reduced ABCC6 activity or expression may lead to lower PPi levels, contributing to pathological calcification in blood vessels and kidneys. Restoring ABCC6 function or enhancing its expression offers a new and compelling therapeutic strategy to prevent the progression of CKD towards end-stage renal disease in addition to reducing large vessel calcification, a major driver of cardiovascular complications in CKD. Key findings RTY-822, an orally administered PFM targeting ABCC6 increased both ABCC6 protein expression and plasma PPi levels in primary human hepatocytes, supporting its proposed mechanism of action In a rat model of CKD and vascular calcification induced by an adenine-enriched diet with calcitriol supplementation: RTY-822 treatment led to statistically significant reductions in vascular calcification in the aorta and the femoral arteries After a six-week treatment course, RTY-822 improved glomerular and tubular kidney functions, with statistically significant reductions in serum creatinine, urea, and cystatin C, and an improved estimated glomerular filtration rate (eGFR) Calcium accumulation in the kidney was also significantly reduced Kidney injury biomarkers were reduced, including a significant decrease in plasma KIM-1 and urinary Lipocalin-2 (NGAL) levels In rats fed an adenine-rich diet without calcitriol supplementation, treatment with RTY-822 resulted in: Improved glomerular and tubular kidney functions Reduced serum creatinine and cystatin C levels Increased eGFR Reduced urinary NGAL levels, a biomarker of acute kidney injury The presentation is available on the Rectify website at About Rectify Pharmaceuticals, Inc. ('Rectify') Rectify is advancing Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. Rectify's PFMs have potential to modulate the activity of wild-type and mutated membrane-bound proteins, a historically difficult challenge with a small molecule approach. The Company's breakthrough product platform enables efficient and rapid discovery of first- and best-in-class small molecule therapies with the potential to address membrane protein dysfunction for treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund. For more information, please visit or follow us on X and LinkedIn. ContactMediaJonathan PappasLifeSci Communicationsjpappas@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL. In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need for safer, more effective therapies for CTCL. The conversation underscored the progress being made with HyBryte™, Soligenix's novel, non-mutagenic photodynamic therapy. 'We need new therapies and access to therapies [for patients],' said Dr. Kim, noting that CTCL is a chronic disease which means that therapies with possible side effects, such as the development of contact dermatitis, sun damage or skin cancer from phototherapy, can become a real issue for patients over time. 'There hasn't been an FDA-approved, new skin-directed therapy for over 10 years, so we really need new ones that are safe and hopefully safer [than the ones currently in use].' Clinical results from ongoing studies have been promising, with Dr. Kim noting that participants have experienced positive outcomes and that the therapy has been well tolerated, with no dropouts due to serious adverse events. "HyBryte™ has a unique mechanism of action, so it doesn't damage DNA, unlike phototherapy, so theoretically it's less mutagenic and there's less risk of skin cancer. It's not systemically absorbed, based on prior studies, and seems to be quite well tolerated in terms of its effects on the local skin area,' added Dr. Kim. As a professor of dermatology at the Hospital of the University of Pennsylvania and Director of the Penn Cutaneous Lymphoma Program, Dr. Kim is keen to continue her research into CTCL with colleagues and patients alike. 'There aren't that many clinical trials going on for early-stage disease,' Dr. Kim stated, adding she is very excited for what lies ahead now that open enrollment in HyBryte™ clinical trials is available. 'Hopefully we can get this over the finish line. We can't thank patients enough; it's so critical for getting new therapies approved.' To watch Dr. Kim's interview and learn more about the real-world clinical study of the treatment of Mycosis Fungoides with Synthetic Hypericin and Visible Light, please visit: About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer (SGX942), and in Behçet's Disease (SGX945). Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). For further information regarding Soligenix, Inc., please visit the Company's website at and follow us on LinkedIn and Twitter at @Soligenix_Inc. This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma or any other studies (including the open-label, investigator-initiated study), there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. Corporate Communications IBN Austin, Texas 512.354.7000 Office Editor@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
